This Article Full Text Full Text (PDF) Supplementary Data Correction (v67,p10097) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deeb, K. K. Articles by Green, J. E. Search for Related Content PubMed PubMed Citation Articles by Deeb, K. K. Articles by Green, J. E.

Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis

¹ Laboratory of Cell Regulation and Carcinogenesis, ² Cell and Cancer Biology Branch, and ³ Biometrics Research Branch, Center for Cancer Research, National Cancer Institute, and ⁴ Genetics of Development and Disease Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland; ⁵ The EMMES Corp., Rockville, Maryland; ⁶ Department of Molecular and Cellular Biology, Baylor College of Medicine; ⁷ Baylor University Cancer Center, Houston, Texas; and ⁸ University of California Irvine, Irvine, California

Requests for reprints: Jeffrey E. Green, Transgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, National Cancer Institute, Room 4054, Building 37, 37 Convent Dr., Bethesda, MD 20892. Phone: 301-435-5193; Fax: 301-496-8709; E-mail: JEGreen{at}nih.gov.

Understanding the genetic architecture of cancer pathways that distinguishes subsets of human cancer is critical to developing new therapies that better target tumors based on their molecular expression profiles. In this study, we identify an integrated gene signature from multiple transgenic models of epithelial cancers intrinsic to the functions of the Simian virus 40 T/t-antigens that is associated with the biological behavior and prognosis for several human epithelial tumors. This genetic signature, composed primarily of genes regulating cell replication, proliferation, DNA repair, and apoptosis, is not a general cancer signature. Rather, it is uniquely activated primarily in tumors with aberrant p53, Rb, or BRCA1 expression but not in tumors initiated through the overexpression of myc, ras, her2/neu, or polyoma middle T oncogenes. Importantly, human breast, lung, and prostate tumors expressing this set of genes represent subsets of tumors with the most aggressive phenotype and with poor prognosis. The T/t-antigen signature is highly predictive of human breast cancer prognosis. Because this class of epithelial tumors is generally intractable to currently existing standard therapies, this genetic signature identifies potential targets for novel therapies directed against these lethal forms of cancer. Because these genetic targets have been discovered using mammary, prostate, and lung T/t-antigen mouse cancer models, these models are rationale candidates for use in preclinical testing of therapies focused on these biologically important targets. [Cancer Res 2007;67(17):8065–80]

This article has been cited by other articles:

				B. C. Trainor, C. Sweeney, and R. Cardiff Isolating the Effects of Social Interactions on Cancer Biology Cancer Prevention Research, October 1, 2009; 2(10): 843 - 846. [Abstract] [Full Text] [PDF]

				A. V. Rathi, M. T. Saenz Robles, P. G. Cantalupo, R. H. Whitehead, and J. M. Pipas Simian Virus 40 T-Antigen-Mediated Gene Regulation in Enterocytes Is Controlled Primarily by the Rb-E2F Pathway J. Virol., September 15, 2009; 83(18): 9521 - 9531. [Abstract] [Full Text] [PDF]

				H. Kadara, L. Lacroix, C. Behrens, L. Solis, X. Gu, J. J. Lee, E. Tahara, D. Lotan, W. K. Hong, I. I. Wistuba, et al. Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System Cancer Prevention Research, August 1, 2009; 2(8): 702 - 711. [Abstract] [Full Text] [PDF]

				P. J. ter Brugge, V. B. T. Ta, M. J. W. de Bruijn, G. Keijzers, A. Maas, D. C. van Gent, and R. W. Hendriks A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen Blood, July 2, 2009; 114(1): 119 - 127. [Abstract] [Full Text] [PDF]

				E. Sotillo, J. Garriga, A. Padgaonkar, A. Kurimchak, J. G. Cook, and X. Grana Coordinated Activation of the Origin Licensing Factor CDC6 and CDK2 in Resting Human Fibroblasts Expressing SV40 Small T Antigen and Cyclin E J. Biol. Chem., May 22, 2009; 284(21): 14126 - 14135. [Abstract] [Full Text] [PDF]

				H. Schayek, K. Haugk, S. Sun, L. D. True, S. R. Plymate, and H. Werner Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor-Dependent Manner Clin. Cancer Res., March 1, 2009; 15(5): 1558 - 1565. [Abstract] [Full Text] [PDF]

				E. Sotillo, J. Garriga, A. Kurimchak, and X. Grana Cyclin E and SV40 Small t Antigen Cooperate to Bypass Quiescence and Contribute to Transformation by Activating CDK2 in Human Fibroblasts J. Biol. Chem., April 25, 2008; 283(17): 11280 - 11292. [Abstract] [Full Text] [PDF]

				Correction: T/t-Antigen Signature in Aggressive Human Cancers Cancer Res., October 15, 2007; 67(20): 10097 - 10097. [Full Text] [PDF]